BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung
Colorectal Cancer
Prostate Cancer
Renal Cancer
Malignant Melanoma

Interventions: Biological: MDX-1106

First Posted Date: 2007-02-28

Last Posted Date: 2015-02-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 39

Registration Number: NCT00441337

Locations: 🇺🇸
Washington University School of Medicine - Barnes Jewish Hospital, St. Louis, Missouri, United States
🇺🇸
Henry Ford Health System, Detroit, Michigan, United States
🇺🇸
Carolina BioOncology Institute, PLLC, Huntersville, North Carolina, United States

and more 1 locations

Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

Phase 1

Completed

Conditions: Metastatic Prostate Cancer

Interventions: Drug: Dasatinib
Drug: Docetaxel

First Posted Date: 2007-02-23

Last Posted Date: 2014-03-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 49

Registration Number: NCT00439270

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Hematology-Oncology Associates Of Rockland, Nyack, New York, United States
🇺🇸
Duke University, Durham, North Carolina, United States

and more 2 locations

A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction

Phase 1

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Brivanib

First Posted Date: 2007-02-21

Last Posted Date: 2011-05-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT00437424

Locations: 🇪🇸
Local Institution, Sevilla, Spain
🇺🇸
University Of Alabama At Birmingham, Birmingham, Alabama, United States
🇺🇸
Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 2 locations

A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)

Phase 1

Completed

Conditions: Tumors

Interventions: Drug: Brivanib

First Posted Date: 2007-02-21

Last Posted Date: 2013-06-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 29

Registration Number: NCT00437437

Locations: 🇺🇸
Dana-Farber Harvard Cancer Care, Boston, Massachusetts, United States
🇺🇸
Wayne State University, Detroit, Michigan, United States
🇺🇸
Duke University Medical Center-Dept Of Medicine, Durham, North Carolina, United States

A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)

Phase 1

Completed

Conditions: Tumors

First Posted Date: 2007-02-15

Last Posted Date: 2009-01-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 4

Registration Number: NCT00435669

Locations: 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

Phase 2

Terminated

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Corticosteroids (prednisone or prednisolone)
Drug: Abatacept
Drug: Mycophenolate mofetil (MMF)

First Posted Date: 2007-02-02

Last Posted Date: 2015-03-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 423

Registration Number: NCT00430677

Locations: 🇺🇸
Wallace Rheumatic Study Center, Los Angeles, California, United States
🇺🇸
Northshore Lij Health System, Lake Success, New York, United States
🇺🇸
Ok Medical Research Foundation, Oklahoma City, Oklahoma, United States

and more 12 locations

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)

Phase 3

Completed

Conditions: Deep Vein Thrombosis
Pulmonary Embolism

Interventions: Drug: Apixaban
Drug: Enoxaparin
Drug: Enoxaparin-matching placebo
Drug: Apixaban-matching placebo

First Posted Date: 2007-01-18

Last Posted Date: 2014-05-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 5407

Registration Number: NCT00423319

Locations: 🇺🇸
Shrock Orthopedic Research, Ft. Lauderdale, Florida, United States
🇺🇸
Orthoarkansas, P.A., Little Rock, Arkansas, United States
🇺🇸
Pab Clinical Research, Brandon, Florida, United States

and more 17 locations

A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection

Phase 1

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: Entecavir

First Posted Date: 2007-01-18

Last Posted Date: 2018-05-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 64

Registration Number: NCT00423891

Locations: 🇺🇸
Connecticut Children'S Medical Center, Hartford, Connecticut, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Mount Sinai School Of Medicine, New York, New York, United States

and more 7 locations

A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

Phase 3

Completed

Conditions: Active Rheumatoid Arthritis

Interventions: Drug: Abatacept
Drug: Placebo

First Posted Date: 2007-01-09

Last Posted Date: 2012-01-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 50

Registration Number: NCT00420199

Locations: 🇬🇧
Local Institution, Leeds, North Yorkshire, United Kingdom

A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin

Phase 1

Completed

Conditions: Cancer (Solid Tumors)

Interventions: Drug: BMS-690514

First Posted Date: 2007-01-09

Last Posted Date: 2016-09-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 37

Registration Number: NCT00420186

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
🇬🇧
Local Institution, Manchester, Greater Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy